Long-term adaptation of renal ion transporters to chronic diuretic treatment
- PMID: 15564765
- DOI: 10.1159/000082314
Long-term adaptation of renal ion transporters to chronic diuretic treatment
Abstract
Loop and thiazide diuretics are clinically useful to induce negative sodium balance. However, with chronic treatment, their effects tend to be blunted since the kidney adapts to diuretics. Molecular identification of the renal ion transporters has provided us with a new understanding of the mechanisms of intrarenal adaptation to diuretics at molecular levels. In the kidney, loop and thiazide diuretics are secreted from the proximal tubule via the organic anion transporter-1 (OAT1) and exert their diuretic action by binding to the Na-K-2Cl cotransporter type 2 (NKCC2) in the thick ascending limb and the Na-Cl cotransporter (NCC) in the distal convoluted tubule, respectively. Recent studies in animal models suggest that abundance of these ion transporters is affected by long-term diuretic administration. Downstream from the primary site of diuretic action, an increase in epithelial Na+ channel (ENaC) abundance is induced by chronic furosemide or hydrochlorothiazide treatment. This adaptation is consistent with previous reports showing cellular hypertrophy and increased Na+ absorption in distal tubular segments. The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively. This compensatory upregulation suggests that either diuretic may activate the ion transporter within the primary site of action. In the proximal tubule, the abundance of OAT1 is increased by chronic treatment with furosemide or hydrochlorothiazide. This upregulation of OAT1 seems to be induced by substrate stimulation, lessening diuretic tolerance associated with long-term diuretic use.
Copyright 2004 S. Karger AG, Basel
Similar articles
-
The target-specific transporter and current status of diuretics as antihypertensive.Fundam Clin Pharmacol. 2012 Apr;26(2):175-9. doi: 10.1111/j.1472-8206.2011.01012.x. Epub 2011 Dec 7. Fundam Clin Pharmacol. 2012. PMID: 22145583 Review.
-
Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats.Am J Physiol Renal Physiol. 2003 Jan;284(1):F133-43. doi: 10.1152/ajprenal.00227.2002. Epub 2002 Sep 24. Am J Physiol Renal Physiol. 2003. PMID: 12388392
-
Mouse model of type II Bartter's syndrome. I. Upregulation of thiazide-sensitive Na-Cl cotransport activity.Am J Physiol Renal Physiol. 2008 Jun;294(6):F1366-72. doi: 10.1152/ajprenal.00608.2007. Epub 2008 Apr 2. Am J Physiol Renal Physiol. 2008. PMID: 18385266
-
[Pharmacologic action of diuretics in the kidney].Ther Umsch. 2000 Jun;57(6):345-50. doi: 10.1024/0040-5930.57.6.345. Ther Umsch. 2000. PMID: 10894017 Review. German.
-
Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney.Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. doi: 10.1093/ndt/gfg186. Nephrol Dial Transplant. 2003. PMID: 12897087
Cited by
-
Regulatory control of the Na-Cl co-transporter NCC and its therapeutic potential for hypertension.Acta Pharm Sin B. 2021 May;11(5):1117-1128. doi: 10.1016/j.apsb.2020.09.009. Epub 2020 Sep 22. Acta Pharm Sin B. 2021. PMID: 34094823 Free PMC article. Review.
-
The Kidney in Heart Failure: The Role of Venous Congestion.Methodist Debakey Cardiovasc J. 2022 Sep 6;18(4):4-10. doi: 10.14797/mdcvj.1121. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 36132580 Free PMC article. Review.
-
The CUL3/KLHL3-WNK-SPAK/OSR1 pathway as a target for antihypertensive therapy.Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1389-96. doi: 10.1152/ajprenal.00132.2016. Epub 2016 Apr 13. Am J Physiol Renal Physiol. 2016. PMID: 27076645 Free PMC article.
-
New insights into combinational drug therapy to manage congestion in heart failure.Curr Heart Fail Rep. 2014 Mar;11(1):1-9. doi: 10.1007/s11897-013-0174-4. Curr Heart Fail Rep. 2014. PMID: 24218088 Review.
-
Furosemide diminishes ¹⁸F-fluoroethylcholine uptake in prostate cancer in vivo.Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2074-82. doi: 10.1007/s00259-014-2829-0. Epub 2014 Jun 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 24952174
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources